About 1,4-alpha-glucan-branching enzyme
1,4-alpha-glucan-branching enzyme (GBE1) is a protein
from Homo sapiens identified by UniProt accession
Q04446, 702 residues long.
MolForge cross-references it against 0 known binders and
216 disease associations.
Target properties
| Protein name | 1,4-alpha-glucan-branching enzyme |
|---|
| UniProt accession | Q04446 |
|---|
| Gene | GBE1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 702 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (216)
Diseases linked to this target (Open Targets).
- glycogen storage disease due to glycogen branching enzyme deficiency · score 0.84
- adult polyglucosan body disease · score 0.79
- glycogen storage disease due to glycogen branching enzyme deficiency, congenital neuromuscular form · score 0.59
- disorder of glycogen metabolism · score 0.56
- glycogen storage disease due to glycogen branching enzyme deficiency, childhood neuromuscular form · score 0.51
- glycogen storage disease due to glycogen branching enzyme deficiency, childhood combined hepatic and myopathic form · score 0.51
- glycogen storage disease due to glycogen branching enzyme deficiency, fatal perinatal neuromuscular form · score 0.51
- genetic disorder · score 0.49
- fetal akinesia deformation sequence · score 0.48
- body mass index · score 0.41
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q04446-F1 | alphafold | PREDICTED | 96.07 | — |
Amino-acid sequence (702 residues)
MAAPMTPAAR PEDYEAALNA ALADVPELAR LLEIDPYLKP YAVDFQRRYK QFSQILKNIG ENEGGIDKFS RGYESFGVHR CADGGLYCKE WAPGAEGVFL TGDFNGWNPF SYPYKKLDYG KWELYIPPKQ NKSVLVPHGS KLKVVITSKS GEILYRISPW AKYVVREGDN VNYDWIHWDP EHSYEFKHSR PKKPRSLRIY ESHVGISSHE GKVASYKHFT CNVLPRIKGL GYNCIQLMAI MEHAYYASFG YQITSFFAAS SRYGTPEELQ ELVDTAHSMG IIVLLDVVHS HASKNSADGL NMFDGTDSCY FHSGPRGTHD LWDSRLFAYS SWEILRFLLS NIRWWLEEYR FDGFRFDGVT SMLYHHHGVG QGFSGDYSEY FGLQVDEDAL TYLMLANHLV HTLCPDSITI AEDVSGMPAL CSPISQGGGG FDYRLAMAIP DKWIQLLKEF KDEDWNMGDI VYTLTNRRYL EKCIAYAESH DQALVGDKSL AFWLMDAEMY TNMSVLTPFT PVIDRGIQLH KMIRLITHGL GGEGYLNFMG NEFGHPEWLD FPRKGNNESY HYARRQFHLT DDDLLRYKFL NNFDRDMNRL EERYGWLAAP QAYVSEKHEG NKIIAFERAG LLFIFNFHPS KSYTDYRVGT ALPGKFKIVL DSDAAEYGGH QRLDHSTDFF SEAFEHNGRP YSLLVYIPSR VALILQNVDL PN
Explore 1,4-alpha-glucan-branching enzyme with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets